These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 8959485)

  • 1. Liposomal doxorubicin.
    Tardi PG; Boman NL; Cullis PR
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
    Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
    Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
    Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD; Dougherty G; Harasym TO; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
    Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
    J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
    Waterhouse DN; Madden TD; Cullis PR; Bally MB; Mayer LD; Webb MS
    Methods Enzymol; 2005; 391():40-57. PubMed ID: 15721373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques.
    Mayer LD; St-Onge G
    Anal Biochem; 1995 Dec; 232(2):149-57. PubMed ID: 8747469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese.
    Chiu GN; Abraham SA; Ickenstein LM; Ng R; Karlsson G; Edwards K; Wasan EK; Bally MB
    J Control Release; 2005 May; 104(2):271-88. PubMed ID: 15907579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
    Theodoulou M; Hudis C
    Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin in ovarian cancer.
    Green AE; Rose PG
    Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.
    Perez-Soler R; Khokhar AR
    Cancer Res; 1992 Nov; 52(22):6341-7. PubMed ID: 1423280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
    Mamasheva E; O'Donnell C; Bandekar A; Sofou S
    Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo].
    Zhang L; Pan H; Liu M; Lu WY
    Yao Xue Xue Bao; 2004 Dec; 39(12):1018-22. PubMed ID: 15813033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.